par Porta, C;Tortora, Giampaolo;Linassier, C;Papazisis, K;Awada, Ahmad 
;Berthold, D;Maroto, J P;Powles, Trevor J;De Santis, Maria
Référence Medical oncology, 29, 3, page (1896-1907)
Publication Publié, 2012-09
;Berthold, D;Maroto, J P;Powles, Trevor J;De Santis, MariaRéférence Medical oncology, 29, 3, page (1896-1907)
Publication Publié, 2012-09
Article révisé par les pairs
| Titre: |
|
| Auteur: | Porta, C; Tortora, Giampaolo; Linassier, C; Papazisis, K; Awada, Ahmad; Berthold, D; Maroto, J P; Powles, Trevor J; De Santis, Maria |
| Informations sur la publication: | Medical oncology, 29, 3, page (1896-1907) |
| Statut de publication: | Publié, 2012-09 |
| Sujet CREF: | Cancérologie |
| Mots-clés: | Bevacizumab |
| Everolimus | |
| Pazopanib | |
| RCC | |
| Renal cell carcinoma | |
| Sequence | |
| Sorafenib | |
| Sunitinib | |
| Temsirolimus | |
| Tyrosine kinase inhibitor | |
| MeSH keywords: | Antineoplastic Agents -- therapeutic use |
| Carcinoma, Renal Cell -- drug therapy | |
| Clinical Trials as Topic | |
| Drug Delivery Systems | |
| Humans | |
| Kidney Neoplasms -- drug therapy | |
| Note générale: | Journal Article |
| Research Support, Non-U.S. Gov't | |
| Review | |
| SCOPUS: re.j | |
| Langue: | Anglais |
| Identificateurs: | urn:issn:1357-0560 |
| info:doi/10.1007/s12032-011-0016-8 | |
| info:scp/84871517868 | |
| info:pmid/21735145 |
